Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

559 Armoring logic-gated CAR T cells with a membrane-tethered IL-12 booster: initial data from the EVEREST-2 study of A2B543 in advanced solid tumors

16 more authors
21 affiliations
  1. 1A2 Biotherapeutics, Inc., Agoura Hills, CA, USA
  2. 2Department of Obstetrics & Gynecology, Stanford University, Palo Alto, California, USA
  3. 3Mayo Clinic, Jacksonville, FL, USA
  4. 47Vanderbilt University, Nashville, TN, USA
  5. 5Critical Care Department, University College Hospital, London, UK
  6. 63H. Lee Moffitt Cancer Center, Tampa, FL, USA
  7. 7Moffitt Cancer Center, Tampa, Florida, USA
  8. 8Mayo Clinic, Rochester, MN, USA
  9. 93UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
  10. 105Mayo Clinic, Rochester, MN, USA
  11. 118University of California San Diego Health, San Diego, CA, USA
  12. 12Banner MD Anderson Cancer Center, Gilbert, AZ, USA
  13. 132UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
  14. 14Fred Hutchinson Cancer Center, Seattle, WA, USA
  15. 15University of California San Diego Moores Cancer Center, San Diego, CA, USA
  16. 16H. Lee Moffitt Cancer Center, Tampa, FL, USA
  17. 17Massachusetts General Hospital, Charlestown, MA, USA
  18. 18The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA
  19. 19Vanderbilt University, Nashville, TN, USA
  20. 20New York University, New York, NY, USA
  21. 21Washington University School of Medicine, Saint Louis, MO, USA

Related

  1. Combining an autoactivated cGAS mutant with membrane-tethered IL-12 via mRNA lipid nanoparticles promotes systemic tumor control
    A. Zhang, Y. Fang, R. Peng +6
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  2. Gallium-68 (68Ga)-Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Initial Staging of High-Risk Prostatic Adenocarcinoma: Reclassification to Oligometastatic Disease and Change in Treatment Intent
    Carlos Paul Villalba-Meneses, Adriana P Noboa, Veronica Marcela Villegas-Paredes
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series
    SHUJI TSUBOTA, GO KANEKO, DAISUKE IGARASHI +3
    In VivoPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaPMC
  4. Extracellular matrix–targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors
    Kaizhao Chen, Qi Fu, Wei Zhang +11
    Science AdvancesPeer-reviewedCC BY-NCOncologyCrossref
  5. Rare Sites of Metastases to the Breast and Integumentary System in Advanced Cervical Cancer at Initial Presentation in Eastern Uganda: A Case Report.
    Julius Goodwill Nteziyaremye, Derrick Akandwanaho, Linda Lutada Adong
    International medical case reports journalPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
BibTeX
@article{mardiros2026armoring,
  title = {{559 Armoring logic-gated CAR T cells with a membrane-tethered IL-12 booster: initial data from the EVEREST-2 study of A2B543 in advanced solid tumors}},
  author = {Armen Mardiros and Oliver Dorigo and Yanyan Lou and Cathy Eng and John Welch and Monica Avila and Kedar Kirtane and Julian Molina and J Randolph Hecht and Antonious Hazim and Peter Vu and Matthew Ulrickson and Jasmine Mitchell and Jennifer M Specht and Sandip P Patel and Frederick L Locke and Marcela V Maus and Jinesh S Gheeya and Kristen K Ciombor and Eric W Ng and Salman R Punekar and Jeffrey P Ward and David B Zhen and David G Maloney and Zachary Yeung and Theodore H Welling and Rosalyn I Marar and Jacqueline D Xuan},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0559},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0559},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 559 Armoring logic-gated CAR T cells with a membrane-tethered IL-12 booster: initial data from the EVEREST-2 study of A2B543 in advanced solid tumors
AU  - Armen Mardiros
AU  - Oliver Dorigo
AU  - Yanyan Lou
AU  - Cathy Eng
AU  - John Welch
AU  - Monica Avila
AU  - Kedar Kirtane
AU  - Julian Molina
AU  - J Randolph Hecht
AU  - Antonious Hazim
AU  - Peter Vu
AU  - Matthew Ulrickson
AU  - Jasmine Mitchell
AU  - Jennifer M Specht
AU  - Sandip P Patel
AU  - Frederick L Locke
AU  - Marcela V Maus
AU  - Jinesh S Gheeya
AU  - Kristen K Ciombor
AU  - Eric W Ng
AU  - Salman R Punekar
AU  - Jeffrey P Ward
AU  - David B Zhen
AU  - David G Maloney
AU  - Zachary Yeung
AU  - Theodore H Welling
AU  - Rosalyn I Marar
AU  - Jacqueline D Xuan
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0559
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0559
SN  - 2051-1426
ER  -